122 related articles for article (PubMed ID: 38062554)
1. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation.
Pan P; Ji D; Li Z; Meng X
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2287990. PubMed ID: 38062554
[TBL] [Abstract][Full Text] [Related]
2. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Inhibition of DCLK1 by Ruxolitinib.
Jang DM; Lim HJ; Hahn H; Lee Y; Kim HK; Kim HS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445192
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a selective inhibitor of doublecortin like kinase 1.
Ferguson FM; Nabet B; Raghavan S; Liu Y; Leggett AL; Kuljanin M; Kalekar RL; Yang A; He S; Wang J; Ng RWS; Sulahian R; Li L; Poulin EJ; Huang L; Koren J; Dieguez-Martinez N; Espinosa S; Zeng Z; Corona CR; Vasta JD; Ohi R; Sim T; Kim ND; Harshbarger W; Lizcano JM; Robers MB; Muthaswamy S; Lin CY; Look AT; Haigis KM; Mancias JD; Wolpin BM; Aguirre AJ; Hahn WC; Westover KD; Gray NS
Nat Chem Biol; 2020 Jun; 16(6):635-643. PubMed ID: 32251410
[TBL] [Abstract][Full Text] [Related]
5. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6
Ferguson FM; Liu Y; Harshbarger W; Huang L; Wang J; Deng X; Capuzzi SJ; Muratov EN; Tropsha A; Muthuswamy S; Westover KD; Gray NS
J Med Chem; 2020 Jul; 63(14):7817-7826. PubMed ID: 32530623
[TBL] [Abstract][Full Text] [Related]
7. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1.
Patel O; Roy MJ; Kropp A; Hardy JM; Dai W; Lucet IS
Commun Biol; 2021 Sep; 4(1):1105. PubMed ID: 34545159
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
10. Autoregulatory control of microtubule binding in doublecortin-like kinase 1.
Agulto RL; Rogers MM; Tan TC; Ramkumar A; Downing AM; Bodin H; Castro J; Nowakowski DW; Ori-McKenney KM
Elife; 2021 Jul; 10():. PubMed ID: 34310279
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury.
Cai B; Xu Y; Luo R; Lu K; Wang Y; Zheng L; Zhang Y; Yin L; Tu L; Luo W; Zheng L; Zhang F; Lv X; Tang Q; Liang G; Chen L
Bioorg Chem; 2024 Apr; 145():107215. PubMed ID: 38394920
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1.
Patel O; Dai W; Mentzel M; Griffin MD; Serindoux J; Gay Y; Fischer S; Sterle S; Kropp A; Burns CJ; Ernst M; Buchert M; Lucet IS
Structure; 2016 Sep; 24(9):1550-61. PubMed ID: 27545623
[TBL] [Abstract][Full Text] [Related]
13. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
[TBL] [Abstract][Full Text] [Related]
14. Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Wang L; Zhao L; Lin Z; Yu D; Jin M; Zhou P; Ren J; Cheng J; Yang K; Wu G; Zhang T; Zhang D
Clin Transl Med; 2022 May; 12(5):e743. PubMed ID: 35522902
[TBL] [Abstract][Full Text] [Related]
15. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
Liu Y; Ferguson FM; Li L; Kuljanin M; Mills CE; Subramanian K; Harshbarger W; Gondi S; Wang J; Sorger PK; Mancias JD; Gray NS; Westover KD
Cell Chem Biol; 2020 Oct; 27(10):1229-1240.e4. PubMed ID: 32755567
[TBL] [Abstract][Full Text] [Related]
16. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.
Kim JH; Park SY; Jeon SE; Choi JH; Lee CJ; Jang TY; Yun HJ; Lee Y; Kim P; Cho SH; Lee JS; Nam JS
Theranostics; 2022; 12(12):5258-5271. PubMed ID: 35910805
[No Abstract] [Full Text] [Related]
17. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
18. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
19. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
